The level of immune response in cancer vaccines can limit application. Here, an immune mobilization strategy, using bacteria-derived nanovesicles, enhances therapeutic outcomes of tumour vaccination by stimulating interleukin-1β secretion to elicit trained immunity with lineage shifts and epigenetic changes in myeloid progenitor pools.
- Guangna Liu
- Nana Ma
- Guangjun Nie
